[{"orgOrder":0,"company":"Sharp HealthCare","sponsor":"The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ampicillin","moa":"Bacterial penicillin-binding protein","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Sharp HealthCare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sharp HealthCare \/ The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi","highestDevelopmentStatusID":"10","companyTruncated":"Sharp HealthCare \/ The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi"},{"orgOrder":0,"company":"Avenacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ampicillin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenacy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for AMPICILLIN/AMPICILLIN TRIHYDRATE

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Avenacy has launched a suite of antibiotic products for injection, including ampicillin, ampicillin and sulbactam, nafcillin, piperacillin and tazobactam.

                          Product Name : Omnipen-N-Generic

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : Ampicillin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Sharp HealthCare

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Sharp HealthCare

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Lead Product(s) : Ampicillin

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Study Phase : Phase III

                          Sponsor : The University of Pittsburgh School of Medicine | Morgan Stanley Children’s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Ampicillin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Premature Birth.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 04, 2023

                          Lead Product(s) : Ampicillin

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Sponsor : The University of Pittsburgh School of Medicine | Morgan Stanley Children’s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank